Kynam Capital Management reduced its position in CG Oncology (NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management sold 1,059,375 shares of CG Oncology during the fourth quarter. The estimated transaction value was $43.84 million, calculated using the period's average closing price. After the sale, the fund held 945,830 shares, valued at $39.27 million at quarter-end. The net position change, reflecting both trading and price effects, was $41.50 million.

The reduction brings CG Oncology to 2.51% of Kynam Capital’s 13F reportable AUM, down from 6.0% the prior quarter.

Top holdings after the filing:

NASDAQ:COGT: $218.99 million (14.3% of AUM)

NASDAQ:VERA: $173.85 million (11.3% of AUM)

NASDAQ:SNDX: $169.15 million (11.0% of AUM)

NASDAQ:CLDX: $161.42 million (10.5% of AUM)

NASDAQ:PCVX: $134.84 million (8.8% of AUM)

As of Friday, CG Oncology shares were priced at $65.08, up 135% over the past year and well surpassing the S&P 500’s roughly 15% gain in the same period.

Metric

Value

Market Capitalization

$5.5 billion

Revenue (TTM)

$4 million

Net Income (TTM)

($160.1 million)

Price (as of Friday)

$65.08

CG Oncology develops and commercializes cretostimogene, a bladder-sparing therapeutic candidate for high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette Guerin (BCG) therapy.

The firm operates as a clinical-stage biopharmaceutical company, generating revenue primarily through clinical development activities and potential future product commercialization.

It targets oncology healthcare providers and patients with high-risk bladder cancer, focusing on those with limited treatment options after BCG therapy failure.

CG Oncology, Inc. is a biotechnology company specializing in innovative therapies for bladder cancer, with a strategic focus on addressing unmet medical needs in high-risk patient populations. The company leverages clinical expertise and a targeted product pipeline to position itself within the oncology therapeutics market. Its lead candidate, cretostimogene, aims to provide a differentiated, bladder-sparing treatment option, enhancing its competitive edge in the evolving biopharmaceutical landscape.

CG Oncology has delivered exactly the kind of performance that might force an investor to consider managing exposure. Shares are up more than 130% over the past year, fueled by growing excitement around cretostimogene and a packed slate of upcoming clinical milestones, including Phase 3 data expected in the first half of 2026. At the same time, this is still a pre-commercial business generating just about $4 million in annual revenue while posting a net loss of roughly $161 million.

To be fair, the company does have a strong balance sheet, with more than $740 million in cash at year-end and closer to $900 million more recently, giving it runway into 2029. But the valuation is still being driven almost entirely by future clinical success, and that might be why Kynam decided to lock in some gains last quarter. The firm’s future performance certainly hinges on upcoming trial readouts, and though positive data could help fuel the surge, there’s also the risk that investors have priced in some pretty lofty expectations.

Before you buy stock in Cg Oncology, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cg Oncology wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*

Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 21, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know was originally published by The Motley Fool